Privia Health Group Inc. (PRVA) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Privia Health Group Inc. (PRVA) advanced +0.71% to $22.00, trading at 31% of its 52-week range ($18.92 – $28.82). Stretched risk/reward at 123x P/E (11% return on capital) under elevated 10-year interest-rate pressure.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry h
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PRVA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PRVA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Privia Health Group Inc. (PRVA) ranks #250 by composite RQD confidence (57/100, grade D+) and #214 by equity capitalization ($2.81B). Within this direct 5-issuer industry benchmark cohort, OPCH leads on earnings valuation at 23.0x trailing P/E, while AVAH leads on capital efficiency and profitability with 15.7% ROIC and 33.3% gross margin. OPCH currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with PRVA at 57/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PRVA
ACTIVE
Privia Health Group Inc. | D+ | 57/100 | 122.6x | — | 10.5% | +0.71% | $2.81B | Benchmark Subject |
| AVAH Aveanna Healthcare Holdings Inc. | C | 65/100 | — | 33.3% | 15.7% | +1.53% | $2.89B | /avah-vs-prva → |
| ADUS Addus HomeCare Corporation | C+ | 69/100 | 24.2x | 32.5% | 9.1% | +1.77% | $2.32B | /adus-vs-prva → |
| WGS GeneDx Holdings Corp. (Class A) | D+ | 58/100 | — | 69.7% | -4.1% | +9.79% | $2.12B | /wgs-vs-prva → |
| OPCH Option Care Health Inc. | B | 75/100 | 23.0x | 19.3% | 11.9% | +1.79% | $4.77B | /opch-vs-prva → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Privia Health Group Inc. (PRVA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $22.9M, operating cash flow of $163.4M, and free cash flow of $163.4M (+49.5% YoY). On the balance sheet, PRVA closed FY2025 with $1.37B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $22.9M | $163.4M | $163.4M | $1.37B | — |
| FY2024 (FY) | 2024-12-31 | $0 | $14.4M | $109.3M | $109.3M | $1.14B | — |
| FY2023 (FY) | 2023-12-31 | $0 | $23.1M | $80.8M | $80.8M | — | — |
As of 2026-11-01, Privia Health Group Inc. (NASDAQ: PRVA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $22.00 (+0.71% 1D, market cap $2.81B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, PRVA ranks #250 in composite RQD confidence.
Within the Health Care sector (Medical/Nursing Services), PRVA carries a Roarable D+ (57/100 RQD), trailing P/E of 122.6x, gross margin of —, and ROIC of 10.5%. By comparison, AVAH (Aveanna Healthcare Holdings Inc.) holds a C grade (65/100 RQD, P/E N/A, ROIC 15.7%, cap $2.89B) and ADUS (Addus HomeCare Corporation) posts a C+ grade (69/100 RQD, P/E 24.2x, ROIC 9.1%, cap $2.32B). Among the 5-stock peer group, OPCH leads on earnings multiple (23.0x) while AVAH leads on capital efficiency (15.7% ROIC).
Per PRVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001759655), Privia Health Group Inc. generated $0 in revenue, $22.9M in net income, and $163.4M in free cash flow against $1.37B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PRVA last traded at $22.00 (+0.71% on volume of 869,002 shares), positioning the stock +5.36% above its 50-day simple moving average ($20.88) and -2.96% below its 200-day simple moving average ($22.67). Across its 52-week range of $18.92 to $28.82, PRVA sits at the 31.1% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±6.0% ($20.68 to $23.32).
Why PRVA Stock advanced +0.71% Today — RQD Quant Desk Flash. Stretched risk/reward at 123x P/E (11% return on capital) under elevated 10-year interest-rate pressure.